enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference.
Share this article
Corporate
Score 85
Bullish
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
Mar 15, 2026 21:33 UTC
ENG, BMY, PFE
Medium term
Related Articles
Score 35
This Community Bank With $9 Billion in Assets Just Drew a $2.5 Million Investor Buy
Mar 15, 22:46
Score 45
Regional Bank Stock Up 14% in a Year as Investor Sells $2.6 Million in Shares
Mar 15, 22:39
Score 45
Billionaires Tepper and Platt Shift AI Holdings Amid Nvidia Exit and 40,000% Gainer Surge
Mar 15, 22:35
Score 85
Bullish
Nvidia Just Spent More Than Iceland's Economy In 30 Days — What Is Jensen Huang Building?
Mar 15, 22:30
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.